Biocompatibility of new peritoneal dialysis solutions: Clinical experience

Peritoneal Dialysis International

Volumn 20, Issue SUPPL. 5, 2001, Pages

  Garcia Lopez, E ^a   Lindholm, B ^a   Tranaeus A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amino acids; Bicarbonate; Biocompatibility; Icodextrin; Peritoneal dialysis solution

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; BICARBONATE; BUFFER; CARBOHYDRATE DERIVATIVE; ESSENTIAL AMINO ACID; EXTRANEAL; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; LACTIC ACID; NEW DRUG; NUTRINEAL; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID; PHYSIONEAL; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FLUID BALANCE; HUMAN; HUMAN TISSUE; HYPEROSMOLALITY; MALNUTRITION; MEDICAL DOCUMENTATION; MESOTHELIUM CELL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM; PH; PRIORITY JOURNAL; RABBIT; SURVIVAL; ULTRAFILTRATION;

AMINO ACIDS; BICARBONATES; DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; PERITONEAL DIALYSIS; TIME FACTORS;

EID: 0035123507     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Peritoneal dialysis
2. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
3. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD
4. Treatment of malnourished CAPD patients with an amino acid based dialysate
5. Bicarbonate-buffered CAPD solutions: From clinical trials to clinical practice
6. A randomized controlled trial of a bicarbonate- and bicarbonate/lactate-containing dialysis solution in CAPD
7. Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes
8. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH
9. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages
10. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions
11. Peritoneal sclerosis. Role of plasticizers
12. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function
13. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD
14. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
15. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
16. Endothelial receptor-mediated binding of glucose-modified album is associated with increased monolayer permeability and modulation of cell surface coagulant properties
17. Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function
18. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD?
19. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain
20. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study
21. Recent developments in osmotic agents for peritoneal dialysis
22. Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis
23. Amino acid-based peritoneal dialysis solutions
24. Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis
25. Peritoneal dialysis with amino acid solutions: Fluid and solute transport kinetics
26. Amino acids as an osmotic agent (instead of glucose) in continuous ambulatory peritoneal dialysis
27. Effective use of amino acid dialysate over four weeks in CAPD patients
28. Alternative use of amino acid and glucose solutions in CAPD
29. Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients-No effect on nutritional status
30. The use of an amino-acid-based CAPD fluie over 12 weeks
31. CAPD with an amino acid dialysis solution: A long-term, cross-over study
32. The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution
33. Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients
34. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study
35. Six-month overnight administration of intraperitoneal amino acids does not improve lean mass
36. A longitudinal study of the effects of amino acid-based
37. Effect of amino acid based dialysis solution on peritoneal permeability and prostanoid generation in patients undergoing continuous ambulatory peritoneal dialysis
38. Effect of alternative osmotic agents on peritoneal transport
39. Supplemented dialysis: Amino acid-based solutions in peritoneal dialysis
40. Malnutrition in continuous ambulatory peritoneal dialysis and use of intraperitoneal amino acids
41. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid
42. Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit
43. History, chemical, and pharmaceutical development of icodextrin
44. Polyglucose solutions in CAPD
45. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance
46. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis
47. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid
48. Cell function and viability in glucose polymer peritoneal dialysis
49. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions
50. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges
51. Icodextrin use in CCPD patients during peritonitis: Ultrafiltration and serum disaccharide concentrations
52. Icodextrin 7.5% dialysate for diurnal exchanges in patients treated with CCPD
53. Interference of icodextrin with serum amylase activity measurement
54. Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients
55. Effect of icodextrin on mesothelial cell growth in culture
56. Peritoneal defense using icodextrin or glucose for daytime dwell CCPD patients
57. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD
58. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD
59. Icodextrin solution (ICO) for ultrafiltration (UF) during peritonitis
60. Peritoneal transport characteristics with glucose polymer based dialysate
61. The effect of glucose polymers on water removal and protein clearances during CAPD
62. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis
63. Improvement of hyperlipidemia with icodextrin use in CAPD patients
64. Lower carbonyl stress in polyglucose or amino acids PD solutions than in conventional glucose-based PD fluids
65. Glycation and advanced glycation end-product formation with icodextrin and dextrose
66. Cell function, viability, and icodextrin
67. Icodextrin hypersensitivity in a CAPD patient
68. Severe cutaneous hypersensitivity requiring permanent icodextrin withdrawal in a CAPD patient
69. Five cases of toxidemia due to icodextrin with 4 cases of severe generalized exfoliative toxidemia
70. Acid-base balance with different CAPD solutions
71. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system
72. Randomized long-term evaluation of bicarbonate-buffered CAPD solution
73. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution
74. Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents
75. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD-final report
76. Effect of two-chambered bicarbonate/lactate-buffered peritoneal dialysis fluids on peripheral blood monuclear cell and polymorphonuclear cell function in vitro
77. In vitro compatibility of a 1.1% amino acid containing peritoneal dialysis fluid with phagocyte function